Centivax is a broad-spectrum vaccine platform technology company. Founded by leading experts in pharmaceutical development, immunology, vaccine science, computational biology, and broadly neutralizing antibody engineering, Centivax is on a mission to accelerate the world’s transition to a post-pathogen humanity. Centivax has developed an epitope-focusing vaccine platform for use in developing broad-spectrum vaccines for rapidly mutating pathogens.
This patented broad-spectrum vaccine platform has demonstrated unprecedented breadth of protection from influenza in ferrets and pigs. Centivax platform development has been backed by the Bill and Melinda Gates Foundation, the National Institute of Health (NIH), the Naval Medical Research Center, the Walter Reed Army Institute of Research, the Medical Technology Enterprise Consortium, the Department of Defense, the National Institute for Innovation in Manufacturing Biopharmaceuticals, NFX, and the Global Health Investment Corporation.